Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: SUPN stock price vs OGE: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at OGE's multiple
Needs OGE P/S.
Implied fair value · at SUPN's multiple
Needs SUPN P/S.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SUPN FY 2025 (ended Dec 31, 2025) · OGE FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SUPERNUS PHARMACEUTICALS, INC. · implied price per share
Bear
$11.78
Base
$13.86
Bull
$15.94
OGE ENERGY CORP. · implied price per share
Bear
$32.56
Base
$38.30
Bull
$44.05
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.02x
1.14x
Net debt / EBITDA
Leverage against operating earnings
-6.69x
3.64x
Cash and equivalents
Liquid reserves on the balance sheet
$496.66M
$200.00K
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
SUPN vs JAZZ
INCYTE CORP
SUPN vs INCY
ANI PHARMACEUTICALS INC
SUPN vs ANIP
Vanda Pharmaceuticals Inc.
SUPN vs VNDA
Harmony Biosciences Holdings, Inc.
SUPN vs HRMY
CENTERPOINT ENERGY INC
SUPN vs CNP
ALLIANT ENERGY CORP
SUPN vs LNT
AMERICAN ELECTRIC POWER CO INC
SUPN vs AEP
XCEL ENERGY INC
SUPN vs XEL
Evergy, Inc.
SUPN vs EVRG
PINNACLE WEST CAPITAL CORP
SUPN vs PNW
$23.23M
$5.66B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SUPN can convert its 89.6% gross margin into sustained operating profitability and positive ROIC, then hold or buy on weakness because the current valuation could be justified by an earnings turnaround; otherwise, OGE-relative data supports trimming exposure because the stock screens expensive versus OGE and the implied downside is 20.2%.
SUPN trades above OGE-implied valuation range and modestly below its historical trading band, but the valuation support is weak given the operating profile. The provided implied price of $38.20 implies 20.2% downside from the current $47.87, suggesting the market is pricing in a richer multiple than OGE-relative framework supports.
Supporting Metrics
